Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 12/20 | 0.77 |
| ▸ | PARP1 | P09874 | 4/20 | 0.77 |
| ▸ | PARP11 | Q9NR21 | 10/20 | 0.72 |
| ▸ | TDP2 | O95551 | 2/20 | 0.58 |
| ▸ | GRM5 | P41594 | 4/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL792895 | 0.87 | PARP10 (1.00) | PARP10PARP1PARP11TDP2PDPK1 | |
| SCHEMBL30549981 | 0.85 | PARP10 (0.69) | PARP10PARP1PARP11TDP2GRM5 | |
| SCHEMBL8159275 | 0.84 | PARP10 (1.00) | PARP10PARP1PARP11TDP2PDPK1 | |
| SCHEMBL1432009 | 0.83 | PARP10 (0.63) | PARP10PARP1PARP11GRM5PDPK1 | |
| SCHEMBL30607099 | 0.83 | TDP2 (0.61) | PARP10PARP1PARP11TDP2GRM5 | |
| SCHEMBL505115 | 0.81 | GRM5 (0.70) | PARP10PARP1PARP11GRM5 | |
| SCHEMBL1725257 | 0.81 | PARP10 (0.59) | PARP10PARP1PARP11GRM5PDPK1 | |
| SCHEMBL1727568 | 0.80 | PARP10 (0.58) | PARP10PARP1PARP11GRM5PDPK1 | |
| SCHEMBL4418018 | 0.79 | MAOA (0.67) | PARP10PARP1PARP11 | |
| SCHEMBL794160 | 0.77 | PARP10 (0.74) | PARP10PARP1PARP11GRM5PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| CN-103108871-B | 17a-hydroxylase/c17,20-lyase inhibitors | NOVARTIS AG | 2014-09-10 | — | — | CN | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| EP-2627648-A1 | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | PARP10 940/4885PARP1 2549/4885PARP11 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.